-
Product Insights
Cromwell Property/ Scarborough Group Intl/ Talbot Green – Cefn yr Hendy Mixed-Use Community – Rhondda Cynon Taf
Equip yourself with the essential tools needed to make informed and profitable decisions with our Cromwell Property/ Scarborough Group Intl/ Talbot Green - Cefn yr Hendy Mixed-Use Community - Rhondda Cynon Taf report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our...
-
Product Insights
Hirwaun Pwr – Cynon Valley Open Cycle Gas Turbine Power Peaking Plant 299 MW – Rhondda Cynon Taf
Equip yourself with the essential tools needed to make informed and profitable decisions with our Hirwaun Pwr - Cynon Valley Open Cycle Gas Turbine Power Peaking Plant 299 MW - Rhondda Cynon Taf report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose...
-
Product Insights
Peripheral Embolic Protection Devices Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Peripheral Embolic Protection Devices Pipeline Market Report Overview Embolic Protection Device(s) EPDs are used to capture and remove plaque debris that are dislodged during interventional procedures. Peripheral Embolic Protection Devices (EPDs) used in the lower extremity, carotid and renal arteries have been accounted for. One unit refers to one EPD. Carotid Embolic Protection Devices and Lower Extremity Embolic Protection Devices are tracked under this segment. Angioplasty: Angioplasty is a minimally invasive interventional procedure that is used to surgically unblock an...
-
Sector Analysis
Hepatitis B Virus Infection – Global Drug Forecast and Market Analysis to 2029
Chronic hepatitis B (CHB) is a serious liver disease caused by the failure of viral clearance following acute hepatitis B virus (HBV) infection. The global disease burden is high in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Brazil, and China); it is especially high in China. For most patients, CHB is a lifelong disease that cannot be cured, with only a very small number of patients entering remission each year. Patients with CHB have a...
-
Sector Analysis
Hepatitis B Virus (HBV) Therapeutics – 5EU Drug Forecast and Market Analysis to 2024
Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths...
-
Sector Analysis
PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2025
Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as...
-
Sector Analysis
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics – Global Drug Forecast and Market Analysis to 2024
Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths...
-
Sector Analysis
Hepatitis B Virus (HBV) Therapeutics – US Drug Forecast and Market Analysis to 2024
Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths...
-
Sector Analysis
Hepatitis B Virus (HBV) Therapeutics – Japan Drug Forecast and Market Analysis to 2024
Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths...
-
Sector Analysis
Hepatitis B Virus (HBV) Therapeutics – China Drug Forecast and Market Analysis to 2024
Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths...